probucol has been researched along with Cardiovascular Stroke in 21 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to evaluate the effects of the antioxidant probucol on myocardial oxidative stress and collagen remodeling by determining type I and III collagen together with relevant collagen mRNA expressions in both the infarcted and noninfarcted myocardium in post-myocardial infarction (MI) rats." | 7.75 | Antioxidant probucol attenuates myocardial oxidative stress and collagen expressions in post-myocardial infarction rats. ( Lei, J; Wang, JF; Zhang, YL; Zhou, SX; Zhou, Y, 2009) |
| "The goal of this study was to evaluate whether reducing the potentially deleterious effects of oxidative stress with the potent anti-oxidant probucol improves prognosis after myocardial infarction (MI) in rats." | 7.71 | Improved post-myocardial infarction survival with probucol in rats: effects on left ventricular function, morphology, cardiac oxidative stress and cytokine expression. ( Adam, A; Liu, P; Parker, TG; Rouleau, JL; Sia, YT; Tsoporis, JN, 2002) |
| " Both, the durable polymer zotarolimus-eluting stent (DP-ZES), the first DES to gain FDA-approval for specific use in patients with diabetes mellitus, and the polymer-free sirolimus- and probucol-eluting stent (PF-SES), with a unique design that enables effective drug release without the need of a polymer offer the potential to enhance clinical long-term outcomes especially in patients with diabetes mellitus." | 5.41 | Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus : Results of the Intracoronary Stenting and Angiographic Results: Test Efficacy ( Aytekin, A; Cassese, S; Coughlan, JJ; Ibrahim, T; Joner, M; Kastrati, A; Kessler, T; Koch, T; Koppara, T; Kufner, S; Laugwitz, KL; Lenz, T; Schunkert, H; Wiebe, J; Xhepa, E, 2021) |
| "This study was designed to evaluate the effects of the antioxidant probucol on myocardial oxidative stress and collagen remodeling by determining type I and III collagen together with relevant collagen mRNA expressions in both the infarcted and noninfarcted myocardium in post-myocardial infarction (MI) rats." | 3.75 | Antioxidant probucol attenuates myocardial oxidative stress and collagen expressions in post-myocardial infarction rats. ( Lei, J; Wang, JF; Zhang, YL; Zhou, SX; Zhou, Y, 2009) |
| "The goal of this study was to evaluate whether reducing the potentially deleterious effects of oxidative stress with the potent anti-oxidant probucol improves prognosis after myocardial infarction (MI) in rats." | 3.71 | Improved post-myocardial infarction survival with probucol in rats: effects on left ventricular function, morphology, cardiac oxidative stress and cytokine expression. ( Adam, A; Liu, P; Parker, TG; Rouleau, JL; Sia, YT; Tsoporis, JN, 2002) |
| "A 62-year-old man with old myocardial infarction and familial hypercholesterolemia was treated by both probucol and low-density lipoprotein (LDL) apheresis." | 3.70 | Long-term effect of low-density lipoprotein apheresis in a patient with heterozygous familial hypercholesterolemia: follow-up study using coronary angiography. ( Arakawa, K; Jimi, S; Naito, S; Nii, T; Okabe, M; Saku, K; Shirai, K; Takeda, Y, 1998) |
| "On day 3 after induction of myocardial infarction, Sprague-Dawley rats were randomized to receive probucol and pyrrolidine dithiocarbamate (MI-T), or vehicle only (MI) for 7 weeks." | 3.70 | Antioxidants attenuate myocyte apoptosis in the remote non-infarcted myocardium following large myocardial infarction. ( Coppey, L; Li, WG; Oskarsson, HJ; Weiss, RM, 2000) |
| "The influence of probucol-induced low high-density lipoprotein (HDL) cholesterolemia on the progression of coronary atherosclerosis was studied in 320 patients with angina pectoris or myocardial infarction, 32 patients with probucol 500 mg/day, 288 patients without probucol, who underwent follow-up angiography at intervals of at least 2 years." | 3.69 | [Influence of low high-density lipoprotein cholesterolemia induced by probucol on the progression of coronary atherosclerosis]. ( Harada, S; Hiasa, Y; Hosokawa, S; Kato, S; Kishi, K; Ohtani, R; Takahashi, T; Tanimoto, M, 1997) |
| " The daily dosage of probucol was 1 g divided into two 500 mg doses." | 2.65 | [A long-term (9 years) clinical study of the safety and efficacy of probucol, and an analysis of morbidity and mortality rates (author's transl)]. ( Cerimelle, BJ; Martz, BL; Taylor, HA; Tedeschi, RE, 1980) |
| "Monitored clinical studies conducted in 1133 patients, involving 3928 patient years of experience with probucol, have shown that it is an effective cholesterol lowering agent and is well tolerated during long term administration (some patients treated for as long as nine years)." | 2.65 | Safety and effectiveness of probucol as a cholesterol lowering agent. ( Cerimele, BJ; Martz, BL; Taylor, HA; Tedeschi, RE, 1982) |
| "Polymer-free DESs are as safe and effective as durable polymer DES; however, there is no evidence of any additional benefits provided by this new technology." | 2.50 | Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. ( Angelini, P; Buffon, A; Cortese, B; de Boer, MJ; Dias, S; Kandzari, D; Kelm, M; Kowalewski, M; Kubica, J; Lansky, A; Navarese, EP; Suryapranata, H; Torguson, R; Waksman, R; Wojakowski, W, 2014) |
| " Thus, long-term administration appears to suppress the progression of atherosclerotic vascular disease in this animal model." | 1.30 | Long-term probucol treatment reverses the severity of myocardial injury in watanabe heritable hyperlipidemic rabbits. ( Aoki, K; Hori, M; Hoshida, S; Igarashi, J; Kuzuya, T; Yamashita, N, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Koch, T | 1 |
| Lenz, T | 1 |
| Joner, M | 1 |
| Xhepa, E | 1 |
| Koppara, T | 1 |
| Wiebe, J | 2 |
| Coughlan, JJ | 1 |
| Aytekin, A | 1 |
| Ibrahim, T | 4 |
| Kessler, T | 1 |
| Cassese, S | 3 |
| Laugwitz, KL | 4 |
| Schunkert, H | 1 |
| Kastrati, A | 5 |
| Kufner, S | 3 |
| Navarese, EP | 1 |
| Kowalewski, M | 1 |
| Cortese, B | 1 |
| Kandzari, D | 1 |
| Dias, S | 1 |
| Wojakowski, W | 1 |
| Buffon, A | 1 |
| Lansky, A | 1 |
| Angelini, P | 1 |
| Torguson, R | 1 |
| Kubica, J | 1 |
| Kelm, M | 1 |
| de Boer, MJ | 1 |
| Waksman, R | 1 |
| Suryapranata, H | 1 |
| Sorges, J | 1 |
| Mehilli, J | 3 |
| Repp, J | 1 |
| Lohaus, R | 1 |
| Lahmann, A | 1 |
| Rheude, T | 2 |
| Massberg, S | 2 |
| Byrne, RA | 4 |
| Harada, Y | 1 |
| Colleran, R | 1 |
| Giacoppo, D | 1 |
| Michel, J | 1 |
| Iijima, R | 1 |
| Schulz, S | 2 |
| Pache, J | 2 |
| Seyfarth, M | 1 |
| Schömig, A | 2 |
| Zhou, SX | 1 |
| Zhou, Y | 1 |
| Zhang, YL | 1 |
| Lei, J | 1 |
| Wang, JF | 1 |
| Hausleiter, J | 1 |
| Fusaro, M | 1 |
| Ott, I | 1 |
| Dong, HM | 1 |
| Huang, L | 1 |
| Zhu, SJ | 1 |
| Geng, ZH | 1 |
| Wu, XJ | 1 |
| Jin, J | 1 |
| Yu, XJ | 1 |
| Qin, J | 1 |
| Xia, HM | 1 |
| Veryard, C | 1 |
| Betge, S | 1 |
| Lutz, K | 1 |
| Roskos, M | 1 |
| Figulla, HR | 1 |
| Recio-Mayoral, A | 1 |
| Kaski, JC | 1 |
| McMurray, JJ | 1 |
| Horowitz, J | 1 |
| van Veldhuisen, DJ | 1 |
| Remme, WJ | 1 |
| Tedeschi, RE | 2 |
| Martz, BL | 2 |
| Taylor, HA | 2 |
| Cerimelle, BJ | 1 |
| Cerimele, BJ | 1 |
| Takahashi, T | 1 |
| Hiasa, Y | 1 |
| Harada, S | 1 |
| Hosokawa, S | 1 |
| Kato, S | 1 |
| Tanimoto, M | 1 |
| Kishi, K | 1 |
| Ohtani, R | 1 |
| Hoshida, S | 1 |
| Yamashita, N | 1 |
| Igarashi, J | 1 |
| Aoki, K | 1 |
| Kuzuya, T | 1 |
| Hori, M | 1 |
| Saku, K | 1 |
| Takeda, Y | 1 |
| Jimi, S | 1 |
| Okabe, M | 1 |
| Shirai, K | 1 |
| Nii, T | 1 |
| Naito, S | 1 |
| Arakawa, K | 1 |
| Oskarsson, HJ | 2 |
| Coppey, L | 2 |
| Weiss, RM | 2 |
| Li, WG | 2 |
| Pfuetze, KD | 1 |
| Dujovne, CA | 1 |
| Sia, YT | 2 |
| Parker, TG | 2 |
| Liu, P | 2 |
| Tsoporis, JN | 2 |
| Adam, A | 2 |
| Rouleau, JL | 2 |
| Lapointe, N | 1 |
| Deschepper, CF | 1 |
| Calderone, A | 1 |
| Pourdjabbar, A | 1 |
| Jasmin, JF | 1 |
| Sarrazin, JF | 1 |
| Butany, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis[NCT00598533] | Phase 4 | 3,002 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Randomized Comparison of 3 Limus Agent-Eluting Stents for the Reduction of Coronary Restenosis[NCT00332397] | Phase 4 | 1,007 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Coroflex ISAR 2000 Extended Postmarket Surveillance Non-Interventional Study[NCT02905214] | 4,369 participants (Actual) | Observational | 2016-01-31 | Completed | |||
| Coroflex ISAR 2000 Postmarket Surveillance Non-Interventional Study[NCT02629575] | 2,877 participants (Actual) | Observational [Patient Registry] | 2014-01-31 | Completed | |||
| Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465] | Phase 4 | 50 participants (Actual) | Interventional | 2017-02-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for probucol and Cardiovascular Stroke
| Article | Year |
|---|---|
Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients.
Topics: Drug-Eluting Stents; Humans; Myocardial Infarction; Polymers; Probucol; Randomized Controlled Trials | 2014 |
Probucol.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Apolipoproteins E; Arteriosclerosis; Cardiovascular | 2000 |
8 trials available for probucol and Cardiovascular Stroke
11 other studies available for probucol and Cardiovascular Stroke
| Article | Year |
|---|---|
Antioxidant probucol attenuates myocardial oxidative stress and collagen expressions in post-myocardial infarction rats.
Topics: Animals; Antioxidants; Collagen; Collagen Type I; Collagen Type III; Diastole; Disease Models, Anima | 2009 |
American Heart Association - Scientific Sessions 2006. Cell therapies for ischemic tissues and treatments for lipid metabolism disorders.
Topics: Animals; Cell- and Tissue-Based Therapy; Cholesterol, LDL; Coronary Disease; Endothelial Cells; Eryt | 2007 |
Oral treatment with probucol in a pharmacological dose has no beneficial effects on mortality in chronic ischemic heart failure after large myocardial infarction in rats.
Topics: Administration, Oral; Animals; Antioxidants; Chronic Disease; Collagen; Heart Failure; Male; Myocard | 2007 |
Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.
Topics: Abciximab; Acute Coronary Syndrome; Amides; Antibodies, Monoclonal; Benzazepines; Clinical Trials as | 2007 |
[Influence of low high-density lipoprotein cholesterolemia induced by probucol on the progression of coronary atherosclerosis].
Topics: Aged; Angina Pectoris; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery | 1997 |
Long-term probucol treatment reverses the severity of myocardial injury in watanabe heritable hyperlipidemic rabbits.
Topics: Administration, Oral; Animals; Antioxidants; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Cor | 1997 |
Long-term effect of low-density lipoprotein apheresis in a patient with heterozygous familial hypercholesterolemia: follow-up study using coronary angiography.
Topics: Anticholesteremic Agents; Blood Component Removal; Coronary Angiography; Coronary Artery Disease; Fo | 1998 |
Antioxidants attenuate myocyte apoptosis in the remote non-infarcted myocardium following large myocardial infarction.
Topics: Analysis of Variance; Animals; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Blotting, Wester | 2000 |
Antioxidant therapy attenuates JNK activation and apoptosis in the remote noninfarcted myocardium after large myocardial infarction.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Apoptosis; Disease Models, Animal; Enzyme Activatio | 2001 |
Improved post-myocardial infarction survival with probucol in rats: effects on left ventricular function, morphology, cardiac oxidative stress and cytokine expression.
Topics: Animals; Antioxidants; Cytokines; Gene Expression; Male; Myocardial Infarction; Myocardium; Norepine | 2002 |
Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat.
Topics: Animals; Antioxidants; Apoptosis; Atrial Natriuretic Factor; Chronic Disease; Disease Models, Animal | 2002 |